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There is growing evidence that tumors are sustained and promoted by inflammatory signals from the
surrounding microenvironment. Two papers by Grivennikov et al. and Bollrath et al. in this issue of Cancer
Cell demonstrate the importance of the interleukin-6 family of proinflammatory cytokines and their down-
stream effector STAT3 in colitis-associated colon cancer.Inflammation is now recognized to be
important in the pathogenesis of many
types of malignancies. For example,
even with close surveillance and appro-
priate treatment of inflammatory bowel
disease (IBD), the risk of colorectal cancer
in the setting of ulcerative colitis remains
substantial. Given its important role in
mediating inflammatory signals, attention
has been focused on the role of NF-kB
and its upstream activator, IKKb, in medi-
ating the link between inflammation and
cancer. NF-kB plays a central role in the
activation of numerous proinflammatory
cytokines in multiple cell types,
including macrophages, T cells,
and epithelial cells. Through
conditional deletions of IKKb,
NF-kB has been shown to play
a procarcinogenic role princi-
pally in immune (myeloid) cells
but also in epithelial cells (Greten
et al., 2004; Maeda et al., 2005).
Given its tight link to NF-kB, IL-6
was an early candidate for the
myeloid-derived factor that
could promote tumorigenesis.
Human patients with colon
cancer were known to have
elevated levels of IL-6. Michael
Karin’s group drew attention
to the elevated levels of IL-6 in
murine models (azoxymethane
plus dextran sodium sulfate
[AOM + DSS]) of colitis-associ-
ated cancer (CAC) (Greten et al.,
2004) and later reported that the
gender bias in liver cancer
susceptibility couldbe largely ex-
plained by the higher serum
levels of IL-6 exhibited by males
(Naugler et al., 2007).
IL-6 belongs to a larger family of cyto-
kines that signal through a common
signaling receptor, gp130, expressed on
many cell types. IL-6 binds to the sIL-6R
receptor (gp80, present either on the cell
surface or in solution), which then induces
dimerization of gp130 chains resulting
in activation of the associated Janus
kinases (JAKs) (Figure 1A). JAKs phos-
phorylate gp130, leading to the recruit-
ment and activation of the STAT3 and
STAT1 transcription factors as well as
other molecules (SHP2, Ras-MAPK, and
PI3K) (Heinrich et al., 2003). The impor-
tance of IL-6 signaling inmediating tumor-
igenesis has been examined in some
studies, and the results are equivocal,
whereby IL-6 inhibits the in vitro growth
of some cell types but appears to promote
the in vivo growth of tumors in models of
prostate, breast, and lung cancers (Knup-
fer and Preiss, 2007). However, none of
these earlier studies examined the role
of IL-6 in an inflammatory model of de
novo tumorigenesis.
In this issue of Cancer Cell, two elegant
papersdemonstrate thatSTAT3, anuclear
transcription factor downstreamof gp130,
is necessary for the growth of
colitis-associated colorectal
cancer in mice (Grivennikov
et al., 2009; Bollrath et al.,
2009). Both groups generated
mice deficient for STAT3 in intes-
tinal epithelial cells (IECs) by
crossing Stat3 floxed mice to
villin-Cre transgenic mice and
demonstrated that both CAC
tumor size and incidence in the
AOM + DSS model of CAC were
markedly reduced in mice lack-
ing STAT3 in IECs. Grivennikov
et al. demonstrate that the
phenotype is remarkably similar
to that seen in IL-6 knockout
mice, and they show that IL-6 is
produced by primarily by bone
marrow-derived myeloid cells.
Conversely, exogenous adminis-
tration of IL-6 to mice during
tumor initiation resulted in an
increase in tumor burden and
multiplicity, while IL-6 adminis-
tration during the late stages of
CAC growth increased tumor
burden. In the study by Bollrath
Figure 1. Autocrine IL-6 Mediates gp130/JAK/STAT3
Signaling and Promotes Tumorigenesis
(A) IL-6 produced by inflammatory and stromal cells within the tumor
microenvironment binds to gp80/gp130, leading to Janus kinase
(JAK) activation and phosphorylation of STAT3, which regulates
expression of genes mediating proliferation and preventing apoptosis.
(B) Activated STAT3 (indicated by brown immunostaining) is found in
tumor cells and inflammatory cells particularly on the invasive edge
of tumors. (A breast carcinoma example is shown.)Cancer Cell 15, February 3, 2009 ª2009 Elsevier Inc. 79
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Previewset al., the investigators also employed
gp130Y757F/Y757F mice, which contain
a mutant gp130 receptor molecule that
shows enhanced STAT3 activity, to
demonstrate a role for increased STAT3
activation in the acceleration of colorectal
cancer. Bollrath et al. also point to
a possible role for IL-11, an IL-6 family
member, as suggested from an earlier
study of gp130 in gastric cancer (Ernst
et al., 2008).
The studies by Grivennikov et al. and
Bollrath et al. suggest that STAT3 appears
to function through increased epithelial
proliferation and protection against AOM-
and DSS-induced epithelial cell apop-
tosis. A similar requirement for STAT3
in de novo skin tumorigenesis was estab-
lished by John DiGiovanni’s group (Chan
et al., 2004). In this two-stage chemical
carcinogenesis model, the mutagen 7,
12-dimethylbenz[a]anthracene (DMBA)
led to a marked increase in the number
of keratinocyte stem cells undergoing
apoptosis in STAT3-deficient mice com-
pared with nontransgenic littermates and
a corresponding decrease in the prolifera-
tive response to 12-O-tetradecanoylphor-
bol-13-acetate (TPA). Thus, STAT3 can
mediate tumorigenesis by protecting cells
from apoptotic stimuli and by promoting
cell-cycle progression.
The studies by Grivennikov et al. and
Bollrath et al. add to the growing
literature regarding the oncogenic impor-
tance of persistently activated STAT3 in
many types of cancer, including colo-
rectal cancer (Yu and Jove, 2004). The
mechanisms of constitutive STAT3 acti-
vation include (among others) both
autocrine and paracrine production of
IL-6 leading to STAT3 phosphorylation.
The current studies suggest a model
whereby STAT3-dependent tumorigen-
esis is mediated by IL-6 signals from the
tumor microenvironment, and indeed,
STAT3 activation in human tumors is often
observed at the invasive front of tumors
adjacent to inflammatory cells (Figure 1A).80 Cancer Cell 15, February 3, 2009 ª2009 EAs a transcription factor, STAT3 princi-
pally mediates its effects by regulating
gene expression. A number of STAT3
target genes including those encoding
Bcl-XL, survivin, Hsp70, cyclin D1, c-
Myc, and others were identified to be up-
regulated during tumor formation in these
current studies that may indeed be
responsible for mediating CAC. However,
not all putative STAT3 target genes were
consistently upregulated. It is suggested
by Bollrath et al. that STAT3 may enhance
nuclear localization of b-catenin (a known
player in colorectal carcinogenesis), and it
is of interest whether there is crosstalk
between the Wnt/b-catenin pathway and
the IL-6/gp130/STAT3 pathway.
Perhaps the most interesting aspect
of these studies is the observation that
DSS-induced mucosal inflammation or
colitis was markedly increased in both
IL-6-deficient mice and in mice lacking
STAT3 in IECs, which correlated with an
increase in the expression of proinflam-
matory cytokines within the colonic
mucosa. It is unclear, however, how
injured IECs lacking STAT3 result in
enhanced production of inflammatory
cytokines and a lower risk of cancer.
One highly speculative hypothesis is that
the increase in AOM + DSS-induced
epithelial apoptosis in the STAT3-defi-
cient mice is sufficient to mediate
enhanced recruitment of acute inflamma-
tory cells that produce proinflammatory
cytokines. It is even possible that this
acute inflammation may be antitumori-
genic, and that STAT3 may influence the
degree or type of inflammation and as
a result modulate tumor formation. Inter-
estingly, in the Grivennikov et al. study,
the number of regulatory T cells increased
and Th17 cells decreased in an IL-6-
dependent manner. Several recent
studies have linked IL-6 to Th17 differenti-
ation, and further work is clearly needed to
determinewhether the qualitative immune
cell makeup of the AOM + DSS-induced
colitis and tumors differs between wild-lsevier Inc.type versus STAT3 IEC-deficient or IL-6-
deficient animals.
In summary, the studies by Grivennikov
et al. and Bollrath et al. demonstrate the
significance of IL-6/STAT3 signaling in
promoting CAC. Furthermore, their find-
ings clearly suggest that inhibitors of IL-6
signaling such as blocking antibodies or
JAK inhibitors, which are presently in clin-
ical trials for other diseases, should be
considered for the treatment of patients
with colorectal cancer.
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